Gross margin from €30,726 to €13,925Result from €23,160 to €7,346Equity from €26,160 to €33,505Debts from €20,630 to €24,071Cash from €21,070 to €34,188
2025 accounts not filed, 114 days past the deadline
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Comparable companies, two years later
In July 2024, 39,327 companies had the same profile as KEPHAS PHARMA has now. Each dot stands for 99 companies, two years later.
95.7%
were still trading
2.4%
stopped another way
1.8%
went bankrupt
Micro
2 to 5 years old
solvency 30% or more
a profit of 5% of the balance sheet or more
Test of the method
The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.
The companies in ten equal groups, from the lowest to the highest expected share
Group
Expected
Actual
1
0.2%
0.2%
2
0.4%
0.5%
3
0.6%
0.6%
4
0.7%
0.8%
5
0.9%
1.0%
6
1.4%
1.6%
7
1.7%
1.8%
8
1.9%
2.0%
9
3.1%
3.3%
10
5.9%
6.4%
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,327 companies, not a prediction for KEPHAS PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0793326574
Incorporation
Founding capital of €3,000, 300 shares · Founded by Name after signing inVisible after signing in · Name hiddenVisible after signing in appointed as director and managing director and permanent representative · published on 09-11-2022 · Gazette deed
First establishment
Rue du Cheval Blanc 55, Pont-à-Celles
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
These companies have the same main activity as KEPHAS PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €48,600 and €64,600, founded between 2020 and 2023.
The 2024 annual accounts show equity of €33,505 and a net result of €7,346. Its solvency ranks better than 72% of 25,611 sector peers (NACE 47) in financial year 2024.
The company has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals.
The company number of KEPHAS PHARMA is 0793.326.574. The VAT number is the same number with BE in front: BE 0793.326.574.
Where is KEPHAS PHARMA based?
The registered office is at Rue du Cheval Blanc 55, 6238 Pont-à-Celles.Company details
What does KEPHAS PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of KEPHAS PHARMA?
KEPHAS PHARMA is a private limited company (BV).
When was KEPHAS PHARMA founded?
KEPHAS PHARMA was founded on 07-11-2022.
Is KEPHAS PHARMA still active?
Yes, KEPHAS PHARMA is an active enterprise in the KBO register.
What is the turnover of KEPHAS PHARMA?
The turnover in financial year 2024 is about €150,000. This figure is estimated from the gross margin of €13,925 and 137 comparable companies (NACE 477). It probably lies between €53,000 and €320,000. It is a rough estimate.Financials
Is KEPHAS PHARMA profitable?
In financial year 2024, KEPHAS PHARMA made a profit of €7,346.
Where can I find the annual accounts of KEPHAS PHARMA?
KEPHAS PHARMA filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2024.
When are the next annual accounts of KEPHAS PHARMA due?
KEPHAS PHARMA had to file the annual accounts for financial year 2025 by 31-07-2026. On 22-11-2026 they are not filed yet, 114 days past the deadline.Timeline